

Applicants : Alexander Gad and Dora Lis
U.S. Serial No.: 09/816,989
Filed : March 23, 2001
Page 2

In the Claims

Please amend claims 123, 133, 152 and 157 in the subject application as set forth below in accordance with 37 C.F.R. §1.121 as amended by 68 Fed. Reg. 38611 (June 30, 2003).

1-122. (Canceled)

123. (currently amended) A method of treating a ~~mammal~~ human afflicted with multiple sclerosis comprising administering to the ~~mammal~~ human a single purified polypeptide, wherein the purified polypeptide comprises consecutive amino acids having an the amino acid sequence of which is set forth in any of SEQ ID NO:2 or SEQ ID NO:7 in an amount effective to treat the ~~mammal~~ human.

124. (previously presented) The method of claim 123 wherein the purified polypeptide consists entirely of L-amino acids.

125-126. (Canceled)

127. (currently amended) The method of claim 123, wherein the ~~purified polypeptide has~~ the amino acid sequence of the consecutive amino acids is set forth in SEQ ID NO: 2.

128-131. (Canceled)

132. (currently amended) The method of claim 123, wherein the ~~purified polypeptide has~~ the amino acid sequence of the consecutive amino acids is set forth in SEQ ID NO: 7.

Applicants : Alexander Gad and Dora Lis
U.S. Serial No.: 09/816,989
Filed : March 23, 2001
Page 3

133. (currently amended) A method of treating a ~~mammal~~ human afflicted with multiple sclerosis comprising administering to the ~~mammal~~ human a pharmaceutical composition comprising a single purified polypeptide, wherein the purified polypeptide comprises consecutive amino acids ~~having an~~ the amino acid sequence of which is set forth in any of SEQ ID NO:2 or SEQ ID NO:7, in an amount effective to treat the ~~mammal~~ human and a pharmaceutically acceptable carrier.

134-151. (Canceled)

152. (currently amended) A method of ~~delaying the onset or preventing or inhibiting the progression~~ of multiple sclerosis in a ~~mammal~~ human afflicted with multiple sclerosis comprising administering to the ~~mammal~~ human a single purified polypeptide, wherein the purified polypeptide comprises consecutive amino acids ~~having an~~ the amino acid sequence of which is set forth in any of SEQ ID NO:2 or SEQ ID NO:7, in an amount effective to ~~delay the onset or prevent or inhibit the progression~~ of multiple sclerosis in the ~~mammal~~ human.

153. (previously presented) The method of claim 152, wherein, the purified polypeptide consists entirely of L-amino acids.

154. (Canceled)

155. (currently amended) The method of claim 152, wherein the ~~purified polypeptide has~~ the amino acid sequence of the consecutive amino acids is set forth in SEQ ID NO: 2.

156. (currently amended) The method of claim 152, wherein the ~~purified polypeptide has~~ the amino acid sequence of the

Applicants : Alexander Gad and Dora Lis
U.S. Serial No.: 09/816,989
Filed : March 23, 2001
Page 4

consecutive amino acids is set forth in SEQ ID NO: 7.

157. (currently amended) A method of delaying ~~the onset~~ or preventing or inhibiting the progression of multiple sclerosis in a ~~mammal~~ human afflicted with multiple sclerosis comprising administering to the ~~mammal~~ human a pharmaceutical composition comprising a single purified polypeptide, wherein the purified polypeptide comprises consecutive amino acids ~~having an the~~ amino acid sequence of which is set forth in any of SEQ ID NO:2 or SEQ ID NO:7, in an amount effective to delay ~~the onset~~ or prevent or inhibit the progression of multiple sclerosis in the ~~mammal~~ human and a pharmaceutically acceptable carrier.

158-166. (Canceled)